Clinical Trial Update: Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing a 4 mg galantamine tablet to Reminyl under fed conditions in healthy subjects; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Galantamine (galantamine)
• Reminyl (galantamine)

Snippet

Sponsor: Actavis Inc. | Conditions: Healthy | Phase 1 | Status: COMPLETED